JP2011153154A - Controlled-release composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a solid dosage formulation for providing controlled-release of a pharmacological agent. <P>SOLUTION: There is provided a solid dosage formulation having: a core tablet with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coating formed and covering the core tablet and containing tramadol dispersed in a second controlled-release matrix from which release of the tramadol is relatively fast. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to solid dosage formulations in which the main component is released over a sustained period of time.

  An important factor affecting the rate of absorption of the active ingredient administered as a tablet or other solid dosage form, and the effectiveness and safety of the resulting formulation, is the dissolution rate of the dosage form in human or animal body fluids.

  Therefore, the ability of the formulation ingredients to affect the rate of release of the active ingredient is the so-called controlled release, extended release, designed to provide slow and uniform release and absorption of the active ingredient over hours, days, weeks or months. Constitutes the basis of sustained-release or long-acting pharmaceutical formulations. Advantages of controlled-release formulations often include improved patient compliance because the required frequency of drug administration is reduced compared to immediate-release dosage forms, and maintains relatively stable blood levels in the body. Therefore, the therapeutic effect is maintained over the set time, and the incidence and intensity of undesirable side effects of the active ingredient are reduced by reducing the increase in plasma concentration that often occurs in immediate release dosage forms. It is.

  Many materials have been proposed and developed as bases for the purpose of controlling the release of active ingredients, ie, drugs and prodrugs. These include polymeric materials such as polyvinyl chloride, polyethylene amides, ethyl cellulose, silicon and poly (hydroxymethyl methacrylate). For example, US Pat. No. 3,087,860 to Endicott et al., US Pat. No. 2,987,445 to Levesque et al., Pharm. Acta Helv. 55,174-182 (1980), Korsmeyer's Diffusion Controlled Systems: Hydrogels, Polymers for Controlled Drug Delivery, Ed Tarcha, CRC Press, Boca Raton, Fla. USA (1991) Chapter 2 pages 15-37 and Buri et al., Pharm. Acta Helv. 55, 189-197 (1980).

  High amylose starch is also used for the purpose of controlled release, and specifically, cross-linked high amylase starch has been put into practical use due to recent progress. For example, US Pat. No. 5,456,921 (Mateescu et al.) Published on October 10, 1995, US Pat. No. 5,616,343 (Cartilier et al.) Published on April 1, 1997, US Pat. No. 6,284,273 issued September 4, 2001 (Lenaerts et al.), US Pat. No. 6,419,957 issued on July 16, 2002 (Lenaerts et al.), And 2003 US Pat. No. 6,607,748 (Lenaerts et al.), Published August 19, discloses a dry powder of pharmaceuticals and about 10 to 60% by weight of amylopectin and about 40 to 90% amylose by weight of cross-linked high amylose starch. A solid release controlled oral pharmaceutical dosage unit in the form of a tablet comprising a dry powder of cross-linked high amylose starch comprising a mixture of:

Further examples of controlled release materials include Kollidon® SR sold by BASF AG (Germany), which is about 80% polyvinyl acetate (PVA) and 19% polyvinyl pyrrolidone (povidone) and as a stabilizer. A physical mixture of PVA and povidone, said to be composed of about 0.8% sodium dodecyl sulfate and 0.2% silica. BASF Technical Information (July 2001) can use Kollidon ^™ SR in sustained release matrix dosage forms such as tablets, pellets, and granules, and direct compression, roller compression, wet in the manufacture of pharmaceutical formulations It is disclosed that various techniques such as granulation and extrusion can be used. Furthermore, US Patent Publication No. 2001/0038852 (Kolter et al.) Published on November 8, 2001, US Patent Publication No. 2002/0012701 (Kolter et al.) Published on January 31, 2002, and January 30, 2003. Published US Patent Publication 2003/0021846 (Kolter et al.) And numerous patent publications provide information on PVA-povidone mixtures.

  Prolonged release and controlled release formulations for tramadol have been proposed, US Patent Publication No. 2003/0143270 (Deboeck et al.) Published January 31, 2003, US Patent Publication No. 6, published July 3, 2001, No. 254,887 (Miller et al.), US Patent Publication 2001/0036477 (Miller et al.) Published November 1, 2001, US Patent Publication No. 6,326,027 (Miller) published December 4, 2001 An example is described in International Publication No. WO 03/080031 (CILAG AG et al.) Published on October 2, 2003. “A Comparison of Once-Daily Tramadol with Normal Release Tramadol in the Treatment of Pain in Osteoarthritis,” The Journal of “Adjusted once-daily” tramadol and immediate-release tramadol Rheumatology (2002) 29 (10): 2195-2199; and Bodalia et al., "A Comparison of the Pharmacokinetics, Clinical Efficacy, and Tolerability of Once-Daily Tramadol Tablets with Normal Release Tramadol Capsules," Journal of Pain and Symptom Management (2003 ) 25 (2): 142-149 is published. Citation or identification of any reference in this specification is not intended to be construed as an admission that such reference is available as prior art to the present invention.

The present invention relates to solid dosage formulations that provide controlled release of drugs.

  In one embodiment, the formulation comprises a central tablet in which the drug is dispersed in a first controlled release base comprising a cross-linked high amylose starch from which the drug base release is relatively slow. There is a coating formed over the central tablet, and the coating comprises a drug dispersed in a second controlled release base from which the release rate of the drug is relatively fast.

In the context of the present invention, “relatively fast” means at least twice as fast when individually measuring the initial release rate of the drug under the same conditions for each base material. In order to perform such measurement, preparations having different labels for the drug of the central tablet and the drug of the coating are prepared. For example, in the case of tramadol, the central tablet tramadol can be labeled with ¹⁵ N and the coated tablet tramadol can be labeled with ¹³ C. Many methods are well known to those skilled in the art that allow such compounds to be differentially labeled so that diffusion from the formulation can be tracked without significantly affecting its diffusion rate. If the velocities are sufficiently different from each other, those skilled in the art will recognize such relative velocities from the biphasic behavior observed for drug release from a single formulation, such as those at t = 0 and t = 12 in FIG. Can be estimated to a reasonable approximation. Typically, the measurements are made under the conditions described with respect to FIG.

  In another broad embodiment, the present invention is a solid dosage form having a central tablet with a drug in a first controlled release base. A coating with the drug in the second controlled release base covers the central tablet. The second controlled release base is a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone and the drug release from the center tablet base is relatively slow relative to the drug release from the coating base. . Relatively slow means that the initial release rate of the drug is less than 1/2 when measured individually for each base under the same conditions, and the measurement is performed with a relatively fast measurement as described above. .

  The drug in the central tablet and the coating can be either the same or different embodiments, and in a preferred embodiment, the formulation comprises a single drug that is tramadol.

  In one preferred embodiment of the invention, the central tablet and the coating contain relative amounts of drug such that the release of drug from the formulation is biphasic.

  Preferably, the drug is water soluble and the first base is relatively hydrophilic with respect to the second base.

  Many drugs have the ability to form ionic salts, and this is often the preferred form of drug for inclusion in the formulations of the present invention. Preferred drugs contain at least one amino group, and these are conveniently incorporated in the form of, for example, hydrochloride.

  Preferably, the drug release rate from the coating is at least twice the drug release rate from the central tablet. Other relative rates are possible, and the drug release rate from the coating can be at least three times the release rate from the central tablet; the drug release rate from the coating is up to 15 times the release rate from the central tablet. The drug release rate from the coating may be up to 12 times the drug release rate from the central tablet; the drug release rate from the coating is May be up to 10 times; drug release rate from coating may be up to 8 times drug release rate from central tablet; drug release rate from coating is drug release from central tablet The rate of drug release from the coating may be up to 6 times the rate; alternatively, the rate of drug release from the coating may be about 4 times the rate of drug release from the central tablet. In another embodiment, a biphasic release behavior is observed and the drug release rate from the coating is 3 to 9 times the drug release rate from the central tablet, more preferably the drug release rate from the coating is central. The drug release rate from the tablet is 4 to 8 times, more preferably the drug release rate from the coating is 5 to 7 times the drug release rate from the central tablet.

  In certain embodiments, drug release from 10% to 30% per hour between 0 and 2 hours when tested in vitro in 50 mM phosphoric acid pH 6.8 using a USP Type I apparatus and stirring at 50 to 150 rpm. Is done.

  In some embodiments, 10% to 40% of the drug is released during a measurement of about 0 to 2 hours, and about 30 to 60% of the drug is released during a measurement of 2 to about 7 hours, From about 50% to 80% of the drug is released during about 12 hours of measurement and about 80% to 100% of the drug is released after about 20 hours of measurement.

  The preferred active ingredient of the central tablet and coating is an analgesic, specifically the active ingredient is tramadol.

  The drug of the preparation of the present invention is at least about 1 g / L, or 10 g / L or more, alternatively 100 g / L or more, alternatively 500 g / L or more, alternatively 1000 g / L or more, or 2000 g / L or more. preferable.

  In certain embodiments, the formulations of the present invention have a center tablet to coating ratio (w / w) of about 1 to about 0.1, alternatively about 0.9 to about 0.2, alternatively about 0.8 to about 0. .2, or about 0.7 to about 0.2, alternatively about 0.5 to about 0.2, alternatively about 0.4 to about 0.2, alternatively about 0.35. In this situation, it will be the total weight of the central lock and the total weight of the coating that is taken into account when calculating the weight ratio.

  In some embodiments, the ratio (w / w) of drug in the central tablet to drug in the coating is from about 0.1 to about 10, alternatively from about 0.1 to about 8, alternatively from about 0.2 to about 7, Or about 0.3 to about 6, or about 0.4 to about 5, alternatively about 0.5 to about 4, alternatively about 0.6 to about 3, alternatively about 0.6 to about 2, or about 0.6. To about 1.5, or about 0.6 to about 1.3, alternatively about 0.7 to about 1, alternatively about 0.7 to about 0.9, or about 0.8.

  In specific embodiments of the invention, the formulation is about 10% to about 90% drug weight, or about 20 to about 80% drug weight, or about 30% to about 70% drug weight by weight. %, Or about 40% to about 60% in terms of drug weight, or about 50% in terms of drug weight.

  In specific embodiments, the formulations of the present invention have coatings of about 5% to about 90% drug weight, or about 5% to about 80% drug weight, or about 10% to about 70% drug weight. %, Or from about 10% to about 60% by drug weight, from about 15% to about 50% by drug weight, from about 15% to about 45% by drug weight, or from about 15% by drug weight It is about 40%, or about 20% to about 35% in terms of drug weight, or about 20% to about 30% in terms of drug weight.

  In some embodiments of the invention, the formulation has a coating base to coating drug ratio (w / w) of from about 0.1 to about 10, alternatively from about 0.2 to about 9, alternatively from about 0.2. About 8, or about 0.3 to about 7, alternatively about 0.4 to about 6, alternatively about 0.5 to about 5, alternatively about 0.6 to about 4, alternatively about 0.7 to about 4, or about 1 to about 4, or about 1 to about 3, or about 1.5 to about 2.5.

  In some embodiments, the formulation has a ratio of central tablet base to central tablet drug (w / w) of about 0.1 to about 10, alternatively about 0.2 to about 9, alternatively about 0.3 to about 7, or about 0.4 to about 6, alternatively about 0.5 to about 5, alternatively about 0.5 to about 4, alternatively about 0.5 to about 3, alternatively about 0.6 to about 3, or about 0 7 to about 2 or about 0.8 to 1.5, or about 0.9 to about 1.5, or about 0.9 to about 1.3, or about 1, or about 0.55 is there.

  Preferably, the drug is a single drug that is at least about 0.5 g / mL soluble in water at room temperature (about 21 ° C.).

  In some embodiments, each drug of the formulation contains an acid functional group, a base functional group, or both an acid functional group and a base functional group, and each functional group is present in the form of a salt of such a functional group. Preferably, the drug contains one ionizable functional group and the functional group is at least 90% ionized in gastric acid (0.1 M Cl).

  The drugs of the preparation of the present invention include isonicotinic acid hydrazide, sodium salicylate, pseudoephedrine hydrochloride, pseudoephedrine sulfate, acetaminophen or diclofenac sodium, verapamil, glipizide, nifedipine, felodipine, betahistine, albuterol, acribastine, omeprazole, misoprosol, It can be any one or more of stall, tramadol, oxybutynin, trimebutine, ciprofloxacin and salts thereof. In addition, drugs include antifungal agents such as ketoconazole, acetylsalicylic acid, acetaminophen, paracetamol, ibuprofen, ketoprofen, indomethacin, diflunisal, naproxen, ketorolac, diclofenac, tolmetine, sulindac, phenacetin, piroxicam, mefenamic acid, dextromethorphan, etc. Other non-steroidal anti-inflammatory drugs such as salicylates, pharmaceutically acceptable salts thereof or mixtures thereof.

  Preferably, the formulations of the present invention are prepared by compression. Typically, the center tablet is formed by compression and the coating is then prepared by being compressed over a pre-formed center tablet.

  In a preferred embodiment, the coating is formed from a mixture of polyvinyl acetate and polyvinyl pyrrolidone. The ratio (w / w) of polyvinyl acetate to polyvinyl pyrrolidone in the coating is usually about 6: 4 to 9: 1, or 7: 3 to 9: 2, or about 8: 2.

  The coating often contains a binder and the preferred binder is xanthan gum.

  The formulation can be a tablet and the preferred crosslinked high amylose starch is (a) crosslinked high amylose starch, then (b) chemically modified the crosslinked high amylose starch, then (c) gelatinized and ( d) a chemically modified crosslinked high amylose starch prepared by a process comprising drying to obtain a controlled release excipient powder, wherein the crosslinked high amylose starch is 90% DMSO at 80 ° C. The peak height corresponding to amylose in the cross-linked high amylose starch corresponds to amylose in the high amylose starch before performing (a) when performing solubilization and gel permeation chromatography for about 3 days in Cross-linked high amylose starch characterized by at least 90% of the peak.

  Another process for obtaining cross-linked high amylose starch for the formulations of the present invention is to form a reaction medium comprising a reaction product comprising a cross-linked high amylose starch slurry by (a) cross-linking high amylose starch; (B) The cross-linked high amylose starch slurry from step (a) was chemically modified at a temperature of about 10-90 ° C. for about 1 to about 72 hours, and (c) obtained in step (b). The reaction medium is neutralized with acid, the formed slurry is washed and dewatered as appropriate, or a starch cake or dry powder is formed, (d) the slurry is diluted, or derived from procedure (c) Reslurry the starch cake or the dry powder to adjust the pH to a preferred value between about 3 and about 12, while concentrating from about 2% to about 40% w / w. Forming a slurry, further gelatinizing the slurry at a temperature of about 80 ° C. to 180 ° C. for about 1 second to about 120 minutes, and (e) drying the heat treated product obtained in step (d). Obtaining said controlled release excipient consisting mainly of high amylose starch in the form of a chemically modified and crosslinked powder.

  Another method of producing a controlled release excipient consisting primarily of cross-linked high amylose starch in aqueous medium is (a) high amylose starch chemically at a temperature of about 10 ° C. to about 90 ° C. for about 1 to about 72 hours. To form a reaction medium comprising a chemically modified high amylose slurry by applying a modification, and (b) the chemically modified high amylose starch in the slurry obtained in step (a) (C) neutralize the slurry obtained in step (b) with acid, wash the formed slurry and dehydrate appropriately to form a starch cake or dry to form a dry powder. (D) diluting the slurry or reslurrying the starch cake or the dry powder from step (c) to a pH between about 3 and about 12. Forming a slurry at a concentration of about 2% to about 40% w / w with water while adjusting to a new value, further gelatinizing the slurry at a temperature of about 80 ° C. to 180 ° C. for about 1 second to about 120 minutes; and (e ) Drying the heat treated product obtained in step (d) to obtain said controlled release excipient consisting mainly of high amylose starch in the form of a chemically modified and crosslinked powder.

  Other methods for obtaining cross-linked high amylose starch for the present invention include (a) cross-linking high amylose starch, then (b) chemically modifying the cross-linked high amylose starch, and then (c) gelatin. And (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is solubilized in 90% DMSO at 80 ° C. for about 3 days and subjected to gel permeation chromatography In some cases, the height of the peak corresponding to amylose in the crosslinked high amylose starch is at least 90% of the peak corresponding to amylose in the high amylose starch before performing (a).

  Other methods for obtaining cross-linked high amylose starch for the present invention include (a) cross-linking high amylose starch, then (b) chemically modifying the cross-linked high amylose starch, and then (c) gelatin. And (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is about 20% of the amylose present in the high amylose starch prior to performing (a). Less than% is chemically cross-linked with amylopectin.

  Other methods for obtaining cross-linked high amylose starch for the present invention include (a) cross-linking high amylose starch, then (b) chemically modifying the cross-linked high amylose starch, and then (c) gelatin. And (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is solubilized in 90% DMSO at 80 ° C. for about 3 days and subjected to gel permeation chromatography Sometimes, less than about 20% of the amylose present before carrying out (a) is characterized by chemically cross-linking and eluting with amylopectin.

  Other methods for obtaining cross-linked high amylose starch for the present invention include (a) cross-linking high amylose starch, then (b) chemically modifying the cross-linked high amylose starch, and then (c) gelatin. And (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is solubilized in 90% DMSO at 80 ° C. for about 3 days and subjected to gel permeation chromatography. When performed, the peak height corresponding to amylose is characterized by being higher than the peak corresponding to the entity containing amylopectin.

  Other methods for obtaining cross-linked high amylose starch for the present invention include (a) cross-linking high amylose starch, then (b) chemically modifying the cross-linked high amylose starch, and then (c) gelatin. And (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is about 20% of the amylose present in the high amylose starch prior to performing (a). Less than% is chemically cross-linked with amylopectin.

  Other methods for obtaining cross-linked high amylose starch for the present invention include (a) cross-linking high amylose starch, then (b) chemically modifying the cross-linked high amylose starch, and then (c) gelatin. And (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is solubilized in 90% DMSO at 80 ° C. for about 3 days and subjected to gel permeation chromatography Sometimes, less than about 20% of the amylose present before carrying out (a) is characterized by chemically cross-linking with the amylopectin and eluting together.

  Other methods for obtaining a cross-linked high amylose starch for the present invention include (a) cross-linking the high amylose starch and then (b) chemically modifying the cross-linked high amylose starch and then (c Gelling and (d) drying to obtain a powder of the controlled release excipient, wherein the crosslinked high amylose starch is solubilized in 90% DMSO at 80 ° C. for about 3 days and gel permeation chromatography When performing the graphic, the peak height corresponding to amylose is higher than the peak corresponding to the entity containing amylopectin.

  Of course, products having the structure of cross-linked high amylose starch obtained by one of these methods are within the scope of the present invention, even if the manufacturing process is not identical.

  The center tablet of the formulation of the present invention often contains a lubricant, optionally a hardened vegetable oil.

  In one preferred embodiment, the formulation of the present invention is a tablet formulated for oral administration.

  In one specific embodiment, the present invention provides a central tablet having a drug dispersed in a first controlled release base having a relatively slow release rate of the drug, and a second formed over the central tablet and the second A solid dosage formulation comprising a coating comprising tramadol dispersed in a controlled release base of which the second controlled release base comprises a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone, and of the drug therefrom A solid dosage formulation with a relatively fast release. In another embodiment, the present invention covers a central tablet comprising a drug dispersed in a first controlled release base comprising a cross-linked high amylose starch having a relatively slow drug base release rate, and covering the central tablet A coating comprising a drug formed and dispersed in a second controlled release base, wherein the second controlled release base comprises a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone, and from the central tablet base A solid dosage formulation is provided in which the release of the drug is relatively slow relative to the release of the drug from the coating base.

  Another aspect of the present invention is a solid formulation comprising a central tablet comprising a drug in a first controlled release base and a coating formed over the central tablet and comprising the drug in a second controlled release base. Wherein the second controlled release base comprises a physical mixture of polyvinyl acetate and polyvinylpyrrolidone, and the release of the drug from the central tablet base is relatively slow with respect to the release of the drug from the coating base It is a dosage formulation.

  In another embodiment, the present invention is a solid dosage formulation comprising a drug for release over a long time therefrom, wherein the formulation is a central tablet comprising the drug in a first controlled release base and the controlled release A base tablet comprising a cross-linked high amylose starch, and a coating formed over the central tablet and comprising a drug in a second controlled release base, wherein the second controlled release base comprises polyvinyl acetate and polyvinyl A solid dosage comprising a coating comprising a physical mixture of pyrrolidone and wherein the drug is present in the central tablet sufficiently to release less than 50% of the drug in an aqueous environment, such as gastric acid, within a quarter of the aforementioned time. Contains formulation.

  In such formulations, the time may be from about 12 hours to about 24 hours, and from about 30% to about 70% of the drug is in the central tablet. The drug in the first base and the drug in the second base are at least about 1 g / L, alternatively 10 g / L or more, alternatively 100 g / L or more, alternatively 500 g / L or more, alternatively 1000 g / L or more, or It is preferably 2000 g / L or more and soluble in water. The drug may be an analgesic.

  A specific aspect of the present invention is a solid dosage form for use every 4 hours, every 6 hours, every 8 hours, every 12 hours, or every 24 hours, wherein the preparation comprises a drug containing an amino group A compressed center tablet, wherein the drug is present as a pharmaceutically acceptable salt and is dispersed in a first controlled release base comprising a cross-linked high amylose starch, and covering the center tablet A coating formed by compression and comprising a drug in a second controlled release base, wherein the second controlled release base comprises a coating comprising a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone; and A solid dosage formulation comprising a first phase wherein the drug release from the formulation over the time period has an average release rate over the first 5% of 3 to 8 times the drug release rate in the middle of all hours including.

  In one specific aspect of this specific embodiment, the ratio of drug in the central tablet to drug in the coating (w / w) is from 0.2 to about 7, and the central tablet is by drug weight. 20% to 80%, the coating is about 15% to 50% by drug weight, and the coating base to coating drug ratio (w / w) is 0.3 to 7. Further, the preferred drug is tramadol, and preferably the coating includes a binder.

  In other embodiments, the present invention includes a cross-linked high amylose starch having tramadol and salts thereof, a compressed center tablet embedded therein, and formed by compression over the center tablet, and polyvinyl acetate, polyvinylpyrrolidone , A binder, a controlled release tablet comprising a coating comprising a physical mixture of tramadol and having a central tablet / coating ratio (w / w) of about 0.2 to 0.6, the tramadol and coating in the central tablet In which the ratio of tramadol is about 0.7 to about 1, the ratio of polyvinyl acetate / polyvinylpyrrolidone (w / w) is about 6: 4 to about 9: 1, and pH 6.8 in USPI type apparatus When measuring at 50 to 150 rpm, the tramadol release rate from the coating base is less than the release rate from the central tablet. Is a controlled-release tablet twice.

  The present invention is a method for producing a controlled release drug comprising: (i) mixing a drug and a first base material comprising cross-linked high amylose starch, and (ii) a mixture produced in step (i). (Iii) a drug and a second base material that is released relatively quickly with respect to the first base material, and (iv) a mixture formed in step (iii) Forming as a coating on the outer surface of the central lock.

  The method for producing a controlled release medicament of the present invention comprises (i) mixing a drug and a first base material, (ii) forming the mixture produced in step (i) into a central tablet, and (iii) A second base material, wherein the second base material comprises a physical mixture of polyvinyl acetate and polyvinylpyrrolidone and has a relatively high release rate relative to the first base material. It may include mixing a second base material and (iv) forming the mixture produced in step (iii) as a coating on the outer surface of the central lock.

  Procedure (ii) preferably comprises compressing the mixture produced in procedure (i). Step (iv) involves compressing the mixture produced in step (iii) onto the outer surface of the central lock. The drug in the central tablet and coating is preferably tramadol, where the total amount of tramadol in the drug is effective as a daily dose, and the drug suitably comprises a formulation that is appropriate as defined herein.

The present invention relates to a median time to reach maximum plasma concentration (T _max ) of 2 to 8 hours after a single dose in vivo, and an average plasma concentration obtained 24 hours after a single dose of such a composition An oral tramadol pharmaceutical composition suitable for once daily administration comprising an effective amount of tramadol or a pharmaceutically acceptable salt thereof that results in an average tramadol maximum plasma concentration (C _max ) that is less than 3 times (C _24h ) .

Such compositions shall have an average maximum plasma concentration (C _max ) of less than twice the average plasma concentration (C _24h ) obtained 24 hours after a single dose of such composition. Can do.

In another embodiment, the present invention is an oral tramadol pharmaceutical composition suitable for continuous once daily administration, having an average minimum plasma concentration (C _min ) of 2 to 3 in vivo over a given 24 hour period. A composition comprising an effective amount of tramadol or a pharmaceutically acceptable salt thereof that results in a steady state that results in a maximum mean plasma concentration (C _max ) of double tramadol. According to a specific embodiment, the average C _max does not exceed 350 ng / mL. The average plasma concentration of tramadol is preferably less than 90% of _Cmax for at least 18 hours out of 24 hours.

  The present invention relates to a central tablet comprising a drug dispersed in a first controlled release base comprising a cross-linked high amylose starch, and formed over the central tablet, so that the release of the drug from the formulation is biphasic. A solid dosage formulation comprising a coating comprising tramadol dispersed in a second controlled release base different from the first base.

  According to another embodiment, the present invention provides a central tablet comprising a drug dispersed in a first controlled release base, and a drug formed over the central tablet, wherein the drug release from the formulation is biphasic. A solid dosage formulation comprising a solid formulation comprising a coating comprising tramadol dispersed in a second controlled release base comprising a physical mixture of polyvinyl acetate and polyvinylpyrrolidone.

  According to yet another embodiment, the present invention relates to a central tablet comprising a drug dispersed in a controlled release base comprising a cross-linked high amylose starch, and a physics of polyvinyl acetate and polyvinyl pyrrolidone formed over the central tablet. A solid dosage formulation comprising a coating comprising a drug in a second controlled release base comprising an active mixture.

  In other embodiments, the invention provides about 50 mg, alternatively about 75 mg, or about 100 mg, or about 125 mg, or about 150 mg, or about 175 mg, or about 200 mg, or about 225 mg, dispersed in a controlled release base comprising crosslinked high amylose starch. A central tablet comprising about 250 mg, or about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg of tramadol, and a second comprising a physical mixture of polyvinyl acetate and polyvinylpyrrolidone formed over the central tablet A solid dosage formulation comprising a coating comprising a drug in a controlled release base.

  As used herein, the term “comprising” is used in its non-limiting sentences unless the context indicates otherwise. That is, for example, a formulation that includes the first and second bases can thus also include other components such as a lubricant.

  The formulation of the above formulation provides advantageous properties in vivo as further described below. Accordingly, another aspect of the present invention provides that upon administration of the first dose, the composition provides an onset of analgesia within 2 hours, and the release of tramadol or a salt thereof that lasts at least 24 hours after administration. It is a once-daily oral pharmaceutical composition for control.

  Another embodiment of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition is administered 2 hours after administration when the first dose is administered. Within at least 100 ng / mL and continues to result in an average plasma concentration of at least 100 ng / mL for at least 22 hours after administration.

  Another embodiment of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition is administered 2 hours after administration when the first dose is administered. Within at least 100 ng / mL and continues to result in an average plasma concentration of at least 100 ng / mL for at least 23 hours after administration.

  In another aspect of the invention, the invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition is administered when the first dose is administered. A composition that provides an average plasma concentration of at least 100 ng / mL within 2 hours and continues to provide an average plasma concentration of at least 100 ng / mL for at least 24 hours after administration.

  The once-daily oral pharmaceutical composition of the present invention contains about 200 mg of tramadol or a salt thereof in a preferred embodiment.

  In another aspect, the invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 100 mg of tramadol or a salt thereof, wherein the composition administers an initial dose Wherein the composition results in an average plasma concentration of at least 50 ng / mL within 2 hours of administration and continues to provide an average plasma concentration of at least 50 ng / mL for at least 22 hours after administration.

  In another aspect, the invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 100 mg of tramadol or a salt thereof, wherein the composition administers an initial dose In doing so, a composition is provided that provides an average plasma concentration of at least 50 ng / mL within 2 hours of administration and continues to provide an average plasma concentration of at least 50 ng / mL for at least 23 hours after administration.

  Another aspect of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg tramadol or a salt thereof, wherein the composition administers the first dose In particular, a composition that provides an average plasma concentration of at least 150 ng / mL within 2 hours of administration and continues to provide an average plasma concentration of at least 150 ng / mL for at least 22 hours after administration.

  Another aspect of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg tramadol or a salt thereof, wherein the composition administers the first dose In particular, a composition that provides an average plasma concentration of at least 150 ng / mL within 2 hours of administration and continues to provide an average plasma concentration of at least 150 ng / mL for at least 23 hours after administration.

  Another aspect of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg tramadol or a salt thereof, wherein the composition administers the first dose In particular, a composition that provides an average plasma concentration of at least 150 ng / mL within 2 hours of administration and continues to provide an average plasma concentration of at least 150 ng / mL for at least 24 hours after administration.

  In another embodiment, a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg tramadol or a salt thereof, wherein when the first dose of 400 mg is administered, the composition is at least 22 after administration A composition that provides an average plasma concentration of at least 200 ng / mL over time.

  Another aspect of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg tramadol or a salt thereof, wherein the composition is administered when 400 mg is administered for the first time. A composition that provides an average plasma concentration of at least 190 ng / mL for at least 23 hours after administration.

  Another aspect of the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg tramadol or a salt thereof, wherein the composition is administered when 400 mg is administered for the first time. A composition that provides an average plasma concentration of at least 180 ng / mL for at least 24 hours after administration.

The present invention also provides a once-daily oral pharmaceutical composition having an average maximum plasma concentration (C _max ) of less than 100 ng / mL.

Further, the once-daily oral pharmaceutical composition of the present invention may have an average maximum plasma concentration (C _max ) of less than 300 ng / mL or an average maximum plasma concentration (C _max ) of less than 200 ng / mL. it can.

The once-daily pharmaceutical composition of the present invention may have an average maximum plasma concentration (C _max ) that is less than 2.2 times the average plasma concentration (C _24h ) obtained 24 hours after administration. .

The once daily oral pharmaceutical composition may have an average maximum plasma concentration (C _max ) of less than 300 ng / mL.

The mean maximum plasma concentration (C _max ) can be less than twice the mean plasma concentration (C _24h ) obtained 24 hours after administration.

The mean maximum plasma concentration (C _max ) can be less than 2.3 times the mean plasma concentration (C _24h ) obtained 24 hours after administration.

The once-daily oral pharmaceutical composition of the present invention can provide a median average time to reach maximum blood concentration (t _max ) of 2 to 10 hours, alternatively 3 to 6 hours, alternatively 5 to 6 hours. .

  The present invention also relates to a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof containing 200 mg of tramadol or a salt thereof, wherein the composition is administered when the first dose is administered. Also provided are compositions that provide an average plasma concentration of O-desmethyltramadol of at least 24 ng / mL within 2 hours and continue to provide an average plasma concentration of O-desmethyltramadol of at least 25 ng / mL for at least 24 hours after administration. .

  According to another embodiment, the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 100 mg tramadol or a salt thereof, wherein the composition comprises an initial dose When administered, results in an average plasma concentration of O-desmethyltramadol of at least 11 ng / mL within 2 hours of administration, and results in an average plasma concentration of O-desmethyltramadol of at least 12 ng / mL for at least 24 hours after administration. A continuing composition is provided.

  According to another embodiment, the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg tramadol or a salt thereof, wherein the composition comprises an initial dose When administered, results in an average plasma concentration of O-desmethyltramadol of at least 32 ng / mL within 2 hours of administration, and results in an average plasma concentration of O-desmethyltramadol of at least 32 ng / mL for at least 24 hours after administration. A continuing composition is provided.

  According to another embodiment, the present invention is a once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg tramadol or a salt thereof, wherein the first dose of 400 mg is administered The composition continues to provide an average plasma concentration of O-desmethyltramadol of at least 50 ng / mL within 2 hours of administration, and an average plasma concentration of O-desmethyltramadol of at least 50 ng / mL for at least 24 hours after administration It is a composition.

  One of the objectives of the present invention is to provide flexible dosing options for patients with diverse analgesic requirements with once-daily formulations.

  One embodiment of the invention provides the desired early onset of action when the initial dose of 100 mg is taken, but achieves an average tramadol plasma concentration of at least 45 ng / mL by 2 to 24 hours. It is to provide a formulation.

  A further embodiment of the present invention provides a once-daily formulation that provides the desired early onset of action when the initial dose of 200 mg is taken, but achieves an average tramadol plasma concentration of at least 100 ng / mL by 2 to 24 hours. Is to provide.

  A further embodiment of the present invention provides a once-daily formulation that provides the desired early onset of action when the initial dose of 300 mg is taken, but achieves an average tramadol plasma concentration of at least 150 ng / mL by 2 to 24 hours. Is to provide.

  A further embodiment of the invention provides a once-daily formulation that provides the desired early onset of action when the initial dose of 400 mg is taken, but achieves an average tramadol plasma concentration of at least 180 ng / mL after 2 to 24 hours. It is to be.

Another embodiment of the present invention provides a once-daily formulation that would provide a C ′ _max to dose ratio of about 0.90 to about 1.0 upon taking the first dose. It is.

Other embodiments of the invention would result in a tramadol plasma concentration that rises steadily to achieve a maximum tramadol concentration with a T _max of about 4 hours to about 6 hours when taking the first dose. To provide a once-daily formulation. Preferably, T _max occurs from about 5 hours to about 5.5 hours.

Other embodiments of the present invention appear to result in a tramadol plasma concentration that declines slowly but consistently after _Tmax when taking the first dose, reflecting sustained absorption in addition to the disappearance process. Providing a once-daily formulation. Preferably, the decrease in tramadol plasma concentration after T _max occurs in a log-linear fashion, with an average apparent final elimination half-life of about 5.5 hours to about 6.5 hours.

Another embodiment of the present invention is a slow but steady decline after T _max when taking the first dose, reflecting sustained absorption in addition to the disappearance process, and absorption after T _max. To provide a once-daily formulation that would result in a tramadol plasma concentration lasting at least 20 hours.

Another embodiment of the present invention is that when taking the first dose, it drops to a log-linear form after T _{max and} has an apparent final elimination rate constant (λz) for tramadol plasma concentration of about 0.12 h ^−1. It is to provide a once-daily formulation that results in a tramadol plasma concentration of

  Another embodiment of the present invention provides a once-daily formulation that would result in a mean tramadol residence time (MRT) in the range of about 15 hours to about 18 hours upon taking the first dose. It is.

  Another embodiment of the invention provides a once-daily formulation that would result in a tramadol half-life (HVD) of about 22.5 hours to about 25.4 hours upon taking the first dose. It is to be.

Another embodiment of the present invention provides a ratio of C ′ _max to AUC _0-∞ of from about 0.04 h ⁻¹ to about 0.06 h ⁻¹ once daily, when taking the first dose. To provide a mold formulation. Preferably, the ratio of C ′ _max to AUC _0-∞ is from about 0.04 h ⁻¹ to about 0.05 h ⁻¹ . The C ′ _max / AUC _0-∞ ratio is used to evaluate drug absorption rate.

Another embodiment of the present invention is that when taking the first dose, the average AUC _0-24 for tramadol plasma concentration is proportional to the dose over the range of dose titers 100 mg to 300 mg of the controlled release composition. To provide a once-daily formulation that is likely to increase.

Another embodiment of the present invention provides a once-daily formulation that would result in an AUC _0-Tmax of about 610 ng · h / mL to 630 ng · h / mL when the initial dose of 100 mg is taken It is.

Another embodiment of the present invention provides a once-daily formulation that would result in an AUC _0-Tmax of about 910 ng · h / mL to 920 ng · h / mL when the initial dose of 200 mg is taken It is.

Another embodiment of the present invention provides a once-daily formulation that would result in an AUC _0-Tmax of about 1570 ng · h / mL to 1590 ng · h / mL when the initial dose of 300 mg is taken It is.

Other embodiments of the invention would result in an average ratio of AUC _0-24 / AUC _0-∞ of tramadol plasma concentrations in the range of about 70% to about 85% when taking the first dose 1 It is to provide a once-daily formulation. Preferably, the tramadol plasma concentration AUC _0-24 / AUC _0-∞ is in the range of about 74% to about 80%. As a result, about 15% to about 30% of the administered dose is still circulating in the plasma 24 hours after administration, depending on the administered dose.

Another embodiment of the present invention is that the dose released into the plasma during the first 24 hours when taking the first dose (ie, AUC _0-24 / AUC _{0-∞ dosed} ) Is to provide a once-daily formulation that would have a ratio of C ′ _max to about 1.10 to about 1.35. Preferably, the ratio is about 1.15 to 1.31.

Another embodiment of the invention provides a once-daily formulation where the ratio of C ′ _max / T _max to dose is expected to be about 0.10 to about 0.20 when the first dose is taken It is to be. Preferably, the ratio is about 0.12 to 0.19.

  In another embodiment of the invention, when taking the first dose, the slope of ng / ml · hr units after peak plasma levels would be less than about 0.035 times the total dose in mg. To provide a once-daily formulation. Preferably, the coefficient is about 0.03.

Another embodiment of the present invention is that when the initial dose is taken, the ratio of C ′ _max calculated for plasma O-desmethyltramadol plasma concentration to tramadol dose is about 0.19 to about 0.22. Probable once-daily formulation. Preferably, the ratio is about 0.20 to 0.21.

Another embodiment of the present invention is that the O-desmethyltramadol plasma concentration will increase steadily before the maximum tramadol concentration is achieved at a T _max of about 8 to about 16 hours when taking the first dose. Providing a once-daily formulation.

Another embodiment of the present invention is that O-desmethyltramadol plasma concentration reflects Tramadol absorption and subsequent metabolite formation in addition to the disappearance process after T _max when taking the first dose. Is to provide a once-daily formulation that appears to be gradual but will decline in a consistent manner. Preferably, the decrease in O-desmethyltramadol plasma concentration occurs in a log-linear fashion with an average apparent final elimination half-life of about 6.7 hours to about 8.1 hours.

Another embodiment of the present invention is to provide a once-daily formulation that would result in the formation of metabolites for at least 18 hours after about T _max when taking the first dose.

Another embodiment of the invention is to reduce the O-desmethyltramadol plasma concentration to a log-linear form after T _max when taking the first dose, the apparent final elimination rate for O-desmethyltramadol. The aim is to provide a once-daily formulation that would have a constant (λz) of about 0.1 h ⁻¹ .

  Another object of the present invention is to reduce the half-life (HVD) of O-desmethyltramadol plasma concentration from 25.6 hours to 28.1 hours per day when taking the initial titers of 100 mg, 200 mg and 300 mg. It is to provide a batch formulation.

  Another embodiment of the present invention is a once daily dosage form in which the half-life (HVD) of O-desmethyltramadol is expected to be about 25.6 hours to about 28.1 hours when the first dose is taken. It is to provide a formulation.

Other embodiments of the invention would have a ratio of C ′ _max to AUC _0-∞ calculated for O-desmethyltramadol plasma concentration of about 0.04 h ⁻¹ when taking the first dose. To provide a once-daily formulation. The ratio of C ′ _max / AUC _0-∞ is used to assess the rate of metabolite formation.

In another embodiment of the present invention, the mean AUC _0-24 calculated for O-desmethyltramadol plasma concentration when taking the first dose is in the range of dose titers from 100 mg to 300 mg of the controlled release composition. To provide a once-daily formulation that appears to increase proportionally over dose.

Other embodiments of the invention would have an average AUC _0-Tmax for plasma concentration of O-desmethyltramadol of from about 175 ng · h / mL to 180 ng · h / mL when taking the initial dose of 100 mg To provide a once-daily formulation.

Other embodiments of the invention would have an average AUC _0-Tmax for plasma concentrations of O-desmethyltramadol of from about 530 ng · h / mL to about 550 ng · h / mL when taking the initial dose of 200 mg. Providing a once-daily formulation.

Other embodiments of the invention would have an average AUC _0-Tmax for plasma concentration of O-desmethyltramadol of from about 580 ng · h / mL to about 590 ng · h / mL when taking the initial dose of 300 mg. Providing a once-daily formulation.

Other embodiments of the present invention may have an average AUC _0-24 / AUC _0-∞ ratio of O-desmethyltramadol plasma concentration of about 65% to about 80% when taking the first dose 1 It is to provide a once-daily formulation. Preferably, _the average ratio of AUC _0-24 / AUC _{0-∞ of} O-desmethyltramadol plasma concentration is about 68% to about 75%. As a result, from about 25% to about 32% of the administered dose is still circulating in the plasma 24 hours after administration.

Another embodiment of the present invention is that O-desmethyltramadol plasma 24 hours after administration of C ′ _max calculated for plasma concentration of plasma O-desmethyltramadol relative to the dose of tramadol when taking the first dose. To provide a once-daily formulation that is expected to have a ratio to concentration (AUC _0-24 / AUC _0-∞ multiplied _{by the} tramadol dose) of about 0.0025 to about 0.0035. Preferably, the ratio is from about 0.0027 to about 0.0031.

The various features and advantages of the present invention will become more apparent from the more detailed description given with reference to the accompanying drawings.
The flowchart which shows the manufacturing process of a tablet. Formulations A, B, and C 24-hour dissolution profiles (% RELEASED): in vitro performance of formulations A, B, and C at 50 rpm phosphate buffer pH 6.8, 100 rpm under USPI type conditions . Six tablets were tested for each measurement (TIME). Mean plasma tramadol concentration (ng / ml) 48 hours after administration of the composition (Formulation B) 2 × 200 mg (▲) and twice a day of Tolpagic® LP (Δ) every 12 hours. Plasma concentration was measured using HPLC / UV analysis. Composition (Formulation B) dose 1 × 200 mg once (●), Composition dose 2 × 200 mg (▲), Twice a day every 12 hours, 1 × 100 mg (○) of torpastic (r) LP, and 12 Average O-Desmethyltramadol plasma concentration (ng / mL) 48 hours after administration of twice-daily tolpagic (r) LP1 × 200 mg once (Δ). a: Plasma (PLASMA) 48 hours after a single administration of a tramadol formulation (A, B and C, respectively) with a titer of 100 mg (♦), 200 mg (◯), or 300 mg (Δ) in 27 subjects Tramadol concentration (ng / ml). b: Plasma O-deposition 48 hours after a single administration of a tramadol formulation (A, B and C, respectively) with a titer of 100 mg (♦), 200 mg (◯) or 300 mg (Δ) in 27 subjects. Methyl tramadol concentration (ng / ml). 26 subjects who received the mean steady-state plasma tramadol (●) and O-demethyltramadol (◯) concentration (ng / mL) of 26 subjects who received 200 mg of tramadol formulation B, and 100 mg of twice-daily type topargic LP Mean steady state plasma tramadol (▲) and O-demethyl tramadol (△) concentrations (ng / mL).

(Central lock)
The central tablet of the present invention comprises at least one main component and a base, which are related to control the release of the pharmaceutical component from the base. In a specific embodiment, the center tablet base is known as the Contramid name and recently described in US Pat. No. 6,607,748 (Lenaerts et al.) Published on August 19, 2003. High amylose starch. A preferred formulation in the context of the present invention is provided in the specification of US Pat. No. 6,607,748.

  Preferably, the central tablet is mixed with the ingredients (in the form of granules or powder) and then the mixture is compressed to form the central tablet, after which a coating is formed on top of it. The weight of the central tablet may be any percentage from 10% to 80% of the total weight of the composition. The preferred percentage depends inter alia on the total dose of the drug. In a specific embodiment further described below, the tablet comprises 100 mg of tramadol hydrochloride and the central tablet is about 26% of the tablet weight. In another embodiment, the tablet comprises 200 mg tramadol hydrochloride and the central tablet comprises about 33% of the total tablet weight. In another embodiment, the tablet comprises 300 mg tramadol hydrochloride and the central tablet contributes about 33% of the total weight of the tablet.

(Main ingredient in the center lock)
The active pharmaceutical ingredient is present in the central tablet of the composition of the present invention. Suitable pharmaceutical ingredients of the present invention are any ingredients that are desired to be delivered in the form of sustained release formulations. A comprehensive list of suitable drugs can be found in The Merck Index 12th edition. Preferably, the pharmaceutical ingredient is isonicotinic acid hydrazide, sodium salicylate, pseudoephedrine hydrochloride, pseudoephedrine sulfate, acetaminophen or diclofenac sodium, verapamil, glipizide, nifedipine, felodipine, betahistine, albuterol, acribastine, omeprazole, misoprostoline, tramadol, Trimebutine, ciprofloxacin and salts thereof are not limited thereto. In addition, drugs include antifungal agents such as ketoconazole, or acetylsalicylic acid, acetaminophen, paracetamol, ibuprofen, ketoprofen, indomethacin, diflunisal, naproxen, ketorolac, diclofenac, tolmetine, sulindac, phenacetin, piroxicam, mefenamic acid, dextromethorphan, etc. Other non-steroidal anti-inflammatory drugs such as salicylic acid, pharmaceutically acceptable salts thereof or mixtures thereof. Prodrugs are part of the present invention.

The solubility of the drug in the aqueous solution can vary widely. The solubility of the drug in water is less than 10 ⁻³ g / L, 10 ⁻³ g / L or more, 10 ⁻² g / L or more, 10 ⁻¹ g / L or more, 1 g / L or more, 10 g / L or more, 100 g / L It is good also as L or more, 500 g / L or more, 1000 g / L or more, or 2000 g / L or more. Preferably, the solubility is 100 g / L or more. More preferably, the solubility is 500 g / L or more. Most preferably, the solubility is 1000 g / L or more.

  The drug can meet a variety of dosing conditions. For example, the drug administration condition is less than 1 mg / dosage unit, 1 mg / dosage unit or more, 10 mg / dosage unit or more, 100 mg / dosage unit or more, 200 mg / dosage unit or more, 300 mg / dosage unit or more, 400 mg / dosage unit or more, 500 mg / Dose unit or more, or 1000 mg / dose unit or more. Preferably, the drug is 50 mg / dosage unit or more. More preferably, the drug is 100 mg / dosage unit, or more, such as 150 mg / dosage unit, alternatively 200 mg / dosage unit, alternatively 250 mg / dosage unit, alternatively 300 mg / dosage unit, or more.

  A specific embodiment is a central tablet containing tramadol hydrochloride, wherein the central tablet is about 10% to 90% of the total tramadol present in the tablet, for example about 45 mg of a 100 mg titer tablet (total 45% in tablet). %), Or about 90 mg of the 200 mg titer tablet (45% of the total amount in the tablet), or about 151 mg of the 300 mg titer tablet (50% of the total amount in the tablet).

(Base lock base)
Release of the active pharmaceutical ingredient present in the central tablet from the formulation is slower than the release of the active pharmaceutical ingredient present in the coating base. A preferred base for the center tablet is a cross-linked high amylose starch known by the name of Contramid and described in US Pat. No. 6,607,748. In a specific embodiment, the base comprises from about 10% to about 90% of the weight of the central tablet, i.e. the ratio of the central tablet base to the central tablet main component (w / w) is about 0.1. To about 10, alternatively about 0.2 to about 9, alternatively about 0.2 to about 8, alternatively about 0.3 to about 7, alternatively about 0.4 to about 6, alternatively about 0.5 to about 5, or From about 0.6 to about 4, alternatively from about 0.7 to about 4, alternatively from about 1 to about 4, alternatively from about 1 to about 3, and from about 1.5 to 2.5. In one specific embodiment, the central tablet is about 90 mg total, of which about 44 mg is contramid and about 45 mg is tramadol hydrochloride. Thus, in these examples, Contramid comprises about 49% by weight of the central tablet.

(Optional ingredients)
The central tablet composition of the present invention may optionally contain a pharmaceutically acceptable carrier or medium. Such simple substances or media are well known to those skilled in the art and are identified, for example, in Remingtons's Pharmaceutical Sciences, 14th Edition (1970). Examples of such carriers or media include lactose, starch, dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar. Furthermore, if necessary, suitable binders, lubricants, and disintegrants can be included. If desired, sweeteners or flavors as well as pigments can be included.

  The center tablet composition of the present invention comprises a dispersant such as microcrystalline cellulose, starch, crosslinked starch, crosslinked poly (vinylpyrrolidone), and sodium carboxymethylcellulose, a flavoring agent, a coloring agent, a binder, an antiseptic, and a surfactant. A subcomponent including, but not limited to, may be optionally contained.

  The center lock can also optionally include one or more suitable binders known to those skilled in the art.

  Suitable forms of microcrystalline cellulose include, for example, MCC-PH101, MCC-102, MCC-105, and the like.

  Suitable lubricants as are well known to those skilled in the art can also be included. For example, magnesium stearate, vegetable oil, talc, sodium stearyl fumarate, calcium stearate, stearic acid and the like.

  Suitable fluidizing agents well known to those skilled in the art can also be included. Examples of such fluidizers include, but are not limited to, talc and colloidal silicon dioxide.

(Percentage)
The active ingredient is about 1 to about 90% by weight of the total weight of the central tablet, preferably about 10 to about 70% by weight of the total composition of the central tablet, more preferably about 20 to about 60% by weight of the total composition of the central tablet, And perhaps most is present at a level of about 30 to about 50% by weight of the total core composition.

  Of course, the total amount of all ingredients is 100% by weight, and one skilled in the art can vary the amount within the stated ranges to obtain a useful composition.

(coating)
The dosage form coating comprises a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone, and the active pharmaceutical ingredient of the coating. The coating can include cross-linked high amylose starch such as, for example, contramid and other optional ingredients. In a preferred embodiment, the coating is formed by a dry compression method. The weight of the coating can be any percentage from about 10% to about 90% of the total weight of the composition, but it is preferably a larger portion within this range. Thus, the coating is typically from about 20% to about 90% (w / w) of the tablet of the present invention, alternatively from about 25% to about 90%, alternatively from about 30% to about 85%, alternatively from about 35% to about 85%, Or about 40% to about 85%, alternatively about 45% to about 85%, alternatively about 45% to about 90%, alternatively about 50% to about 90%, or about 50% to about 85%, or about 55% to about 90%, alternatively about 55% to about 85%, alternatively about 55% to about 80%, alternatively about 60% to about 90%, alternatively about 60% to about 85%, alternatively about 60% to about 80%, or about 60% to about 75%, alternatively about 65% to about 90%, alternatively about 65% to about 85%, alternatively about 65% to about 80%, alternatively about 65% to about 75%, alternatively about 65% to about 70 Or make up about 75 percent. The coating often includes an optional binder.

(Coating polyvinyl acetate and polyvinylpyrrolidone)
The weight percentage of the polyvinyl acetate / polyvinylpyrrolidone mixture in the coating can be any of a wide range of values. Depending on the solubility of the main component in the coating in water, the amount of the polyvinyl acetate / polyvinylpyrrolidone mixture can be adjusted. US Patent Publication No. 2001/0038852 describes how such an adjustment can be made. For example, for a water soluble to very soluble main component, the polyvinyl acetate / polyvinyl pyrrolidone mixture is about 20 to about 80%, preferably about 30 to about 65%, or about 40 to about 50% by weight of the coating. It can be. In the specific embodiment shown below, Kollidon ^™ SR comprises about 45% of the weight of the coating, where tramadol hydrochloride is about 31% by weight and xanthan gum is about 23%. As described in US Patent Publication No. 2001/0038852, the amount of polyvinyl acetate / polyvinyl pyrrolidone mixture is often less for those components that are slightly less soluble in water to less soluble.

  The weight ratio of polyvinyl acetate to polyvinyl pyrrolidone in the polyvinyl acetate / polyvinyl pyrrolidone mixture can be in a wide range of values. Preferably, such ratio is about 6: 4 to 9: 1, more preferably about 7: 3 to 6: 1, and more preferably about 8: 2.

  The molecular weight of the polyvinyl acetate component in the polyvinyl acetate / polyvinyl pyrrolidone mixture can be in a wide range of values. Preferably, the average molecular weight of the polyvinyl acetate is from about 100 to about 10,000,000, alternatively from about 1,000 to about 1,000,000, alternatively from about 10,000 to about 1,000,000, alternatively about 100, 000 to about 1,000,000, or about 450,000.

  The molecular weight of the polyvinylpyrrolidone component in the polyvinyl acetate / polyvinylpyrrolidone mixture can be in a wide range of values. The average molecular weight of polyvinylpyrrolidone is from about 100 to about 10,000,000, alternatively from about 1,000 to about 1,000,000, alternatively from about 5,000 to about 500,000, alternatively from about 10,000 to about 100,000. Or about 50,000.

  Polyvinyl acetate and polyvinyl pyrrolidone mixtures can be prepared by a variety of methods such as simply mixing polyvinyl pyrrolidone and polyvinyl acetate powders. In a preferred embodiment, such a mixture is a powder obtained by spray drying a colloidal dispersion of a polyvinyl acetate and polyvinylpyrrolidone solution. Optionally, sodium lauryl sulfate is used as a stabilizer to prevent agglomeration during the spray drying operation and / or colloidal silica is used to improve the flowability of the polyvinyl acetate / polyvinylpyrrolidone mixture. Polyvinyl acetate and polyvinylpyrrolidone can arbitrarily form a random or block copolymer.

(Optional ingredients)
Binders suitable for the present invention include, but are not limited to, plant extracts, gums, synthetic or natural polysaccharides, polypeptides, alginic acids, synthetic polymers or mixtures thereof.

  Suitable plant extracts used as a gelling agent include, but are not limited to, agar, ispacula, psyllium, quince, carob, or mixtures thereof.

  Suitable gums used as gelling agents include, but are not limited to, xanthan gum, guar gum, gum arabic, Indian gum, karaya gum, tragacanth gum or mixtures thereof.

  Suitable synthetic or natural hydrophilic polysaccharides used as gelling agents are hydroxyalkyl cellulose, cellulose ether, cellulose ester, nitrocellulose, dextrin, agar, carrageenan, pectin, flucellaran, starch or starch derivatives, cross-linked high amylose starch, or Including but not limited to the mixture.

  Suitable polypeptides used as gelling agents include, but are not limited to gelatin, collagen, polyserine or mixtures thereof.

  Suitable alginic acids used as gelling agents include, but are not limited to, alginic acid, propylene glycol alginate, sodium alginate or mixtures thereof.

  Suitable synthetic polymers used as gelling agents include carboxyvinyl polymer, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, copolymers of ethylene oxide and propylene oxide, and copolymers or mixtures thereof. It is not limited.

  In a preferred embodiment, the gelling agent is a gum such as xanthan gum, guar gum, gum arabic, Indian gum, Karaya gum, tragacanth gum or mixtures thereof, PEO 7,000,000 and HPMC K100M.

In the most preferred embodiment, the gelling agent is xanthan gum.

(Main drug in coating)
Suitable active pharmaceutical ingredients of the present invention are any active ingredients that are desired to be delivered in the form of sustained release formulations. A comprehensive list of suitable drugs can be found in The Merck Index 12th edition. Preferably, the drug is isonicotinic acid hydrazide, sodium salicylate, pseudoephedrine hydrochloride, pseudoephedrine sulfate, acetaminophen or diclofenac sodium, verapamil, glipizide, nifedipine, felodipine, betahistine, albuterol, acribastine, omeprazole, misoprostol, tramadol ), Oxybutynin, trimebutine, ciprofloxacin and salts thereof, but not limited thereto. In addition, drugs include antifungal agents such as ketoconazole, acetylsalicylic acid, acetaminophen, paracetamol, ibuprofen, ketoprofen, indomethacin, diflunisal, naproxen, ketorolac, diclofenac, tolmetine, sulindac, phenacetin, piroxicam, mefenamic acid, dextromethorphan, etc. Other analgesics, other non-steroidal anti-inflammatory drugs such as salicylic acids, pharmaceutically acceptable salts thereof or mixtures thereof.

The solubility of the drug in the aqueous solution can take a wide range of values. The solubility of the drug in water is less than 10 ⁻³ g / L, 10 ⁻³ g / L or more, 10 ⁻² g / L or more, 10 ⁻¹ g / L or more, 1 g / L or more, 10 g / L or more, 100 g / L L or more, 500 g / L or more, 1000 g / L or more, or 2000 g / L or more may be sufficient. Preferably, the solubility is 100 g / L or more. More preferably, the solubility is 500 g / L or even 1000 g / L or more.

  The drug can meet a variety of dosing conditions. For example, the drug administration condition is less than 1 mg / dosage unit, 1 mg / dosage unit or more, 10 mg / dosage unit or more, 100 mg / dosage unit or more, 200 mg / dosage unit or more, 300 mg / dosage unit or more, 400 mg / dosage unit or more, 500 mg / More than the dosage unit, or 1000 mg / dose unit or more. Preferably, the drug is 50 mg / dosage unit or more. More preferably, the drug is 100 mg / dosage unit or more. Most preferably, the drug is 200 mg / dosage unit or more.

  The coating is from about 5% to about 90% of the active pharmaceutical ingredient (api) weight, or from about 5% to about 80% of the api weight, or from about 10% to about 70% of the api weight, or about api weight. 10% to about 60%, about 15% to about 50% of the api weight, or about 15% to about 45% of the api weight, about 15% to about 40% of the api weight, or about 20% to about 20% of the api weight 35%, or about 20% to about 30% of the api weight.

  In the specific embodiment shown below, the weight of tramadol derived from 100 mg tramadol tablets is about 21% of the weight of the coating. The weight of tramadol from the 200 mg tablet is about 31% of the weight of the coating. The weight of tramadol from the 300 mg tablet is about 30% of the weight of the coating.

(Administration route)
The tablet composition of the present invention can be administered by many routes including, but not limited to, oral, sublingual and rectal. The preferred route of administration of the composition of the present invention is oral.

Compositions of the present invention suitable for oral administration can be presented as discrete units such as tablets or granules. Preferably, the composition of the present invention is provided in the form of a tablet. Such tablets may be formed by compression or molding as is conventional. Compressed tablets may be prepared by compressing a mixture of one or more of the above ingredients in a suitable machine. Molded tablets may be produced by punching out the above ingredients in a suitable machine and can be appropriately moistened with an inert liquid solvent. The tablets may be coated as appropriate and / or with other identifying markings visible to the consumer. The tablet can be in various forms such as a naked tablet, a dry coat tablet, and a film coat tablet. Tablets can also have a variety of shapes (eg, oval, spherical, etc.) and sizes. A comprehensive discussion of tablets can be found in references such as The Theory and Practice of Industrial Pharmacy 3rd edition, Lachman et al. (Lea & Febiger, 1986).
(Dissolution profile of sustained release composition)

  The active ingredient of the composition exhibits the following in vitro dissolution profile when measured with a USPI type apparatus at 50 mM phosphoric acid pH 6.8 and with stirring at 50 to 150 rpm.

  When tested in vitro using a USP Type I apparatus in 50 mM phosphoric acid pH 6.8 and stirring at 50 to 150 rpm, drug is released at a rate of 10% to 30% per hour between 0 and 2 hours, or

  10% to 40% of drug is released from the formulation at 0 to about 2 hours, about 30 to 60% of drug is released from the formulation at 2 to about 7 hours, and 7 to about 12 hours of measurement. About 50% to 80% of the drug is released from the formulation, and about 80% to 100% of the drug is released from the formulation after about 20 hours of measurement, and more preferably

  15% to 35% drug is released from the formulation during the 2 hour measurement, about 40 to 60% drug is released from the formulation during the 7 hour measurement, and about 60% from the formulation during the 12 hour measurement. 80% of the drug is released, and about 85% to 100% of the drug is released after about 20 hours of measurement, or

  20% to 40% drug is released from the formulation during the 2 hour measurement, about 40% to 60% drug is released from the formulation during the 7 hour measurement, and about 60% from the formulation during the 12 hour measurement. % To 80% of the drug is released, and about 85% to 100% of the drug is released when measured after about 20 hours

  The present invention may be understood more readily by reference to the following examples, which are intended to illustrate but not to limit the scope of the invention.

  The cross-linked high amylose starch used in these examples is formed by a method that includes a procedure of cross-linking and chemically modifying, followed by gelatinization and drying. Such a method is described in more detail in U.S. Patent Publication No. 6,607,748 (Lenaerts et al.), Published on August 19, 2003, and is known in the market under the name Contramid®, And described in Examples I and II.

Example I
(A. Cross-linking)
Amylose starch (3.0 kg) (Cl AmyloGel 03003) containing about 70% w / w amylose is charged to the reactor. To this reactor is added water (55.0 L) containing sodium hydroxide (33.0 g) and sodium sulfate (2.40 kg). The resulting slurry is heated to a temperature of 30 ° C. Phosphorous oxychloride (22.5 g) is added to the reaction mixture and allowed to react for 1 hour.

(B. Chemical modification, hydroxypropylation)
Transfer the crude reaction mixture from Section A to a hydroxypropylation reactor. The reaction mixture is heated at 40 ° C. for 30 minutes and the reaction is further purged with nitrogen. After complete purging, propylene oxide (1.80 kg) is added. The reaction mixture is held at 40 ° C. for 20 hours. The reaction mixture is neutralized to pH 5.5 using 0.1N H2S04 (1: 2 v / v). The starch slurry is washed in a basket centrifuge with a centrifugal speed of 1200 rpm. The resulting starch cake is reslurried with 35 L of water and subjected to a second centrifugation. The resulting starch cake is dried in a flash dryer at an inlet temperature of 160 ° C and an outlet temperature of 60 ° C.

(C. Gelatinization)
The modified granular starch cake is diluted with deionized water to form a slurry having a concentration of about 8% calculated from the dry matter weight. The specific gravity of the produced slurry with respect to water is 1.032 kg / L. Adjust the pH of the modified starch slurry to 6.0. The slurry is then heated to 160 ° C. by direct steam injection (Schlick Model 825). The temperature fluctuation is 1 ° C. or less. The slurry is held in a holding column for 4 minutes at 160 ° C. and a pressure of 5.5 bar. The pressure is then reduced to atmospheric pressure by passing a flash. The slurry is then held in a holding tank at 95 ° C.

(D. Spray drying)
Drying the slurry from Section C using a NiroFSD4 spray drying tower equipped with a 0.8 mm nozzle and fed at 10 L / hr. The inlet temperature is fixed at 300 ° C. and the outlet temperature is fixed at 120 ° C. The resulting powder is a controlled release excipient having the following characteristics:

Example II
(A. Cross-linking)
High amylose starch (30.0 kg) containing about 70% w / w amylose (Cl AmyloGel 03003) is charged to the reactor. To this reactor is added water (55.0 L) containing sodium hydroxide (33.0 g) and sodium sulfate (2.40 kg). The resulting slurry is heated to a temperature of 30 ° C. Sodium trimetaphosphate (45 g) is added to the reaction mixture and allowed to react for 1 hour.

(B. Chemical modification, hydroxypropylation)
Transfer the crude reaction mixture from Section A to a hydroxypropylation reactor. The reaction mixture is heated at 40 ° C. for 30 minutes and the reaction is further purged with nitrogen. After complete purging, propylene oxide (1.80 kg) is added. The reaction mixture is held at 40 ° C. for 20 hours. The reaction mixture is neutralized to pH 5.5 with 0.1N H2S04 (1: 2 v / v). The starch slurry is washed in a basket centrifuge with a centrifugal speed of 1200 rpm. The resulting starch cake is reslurried with 35 L of water and subjected to a second centrifugation. The resulting starch cake is dried in a flash dryer at an inlet temperature of 160 ° C and an outlet temperature of 60 ° C.

(C. Gelatinization)
The modified granular starch cake is diluted with deionized water to form a slurry with a concentration of about 8% calculated on dry matter. The specific gravity of the produced slurry with respect to water is 1.032 kg / L. Adjust the pH of the modified starch slurry to 6.0. The slurry is then heated to 160 ° C. by direct steam injection (Schlick Model 825). Temperature variation does not exceed 1 ° C. The slurry is held in a holding column for 4 minutes at 160 ° C. and a pressure of 5.5 bar. The pressure is then reduced to atmospheric pressure by passing a flash. The slurry is then held in a holding tank at 95 ° C.

(D. Spray drying)
Drying of the slurry from Section C is performed using a NiroFSD4 spray drying tower equipped with a 0.8 mm nozzle and fed at 10 L / hour. The inlet temperature is fixed at 300 ° C. and the outlet temperature is fixed at 120 ° C. The resulting powder is a controlled release excipient having the following characteristics:

Love TAB O is a product sold by Penwest Pharmaceutical Co., Ltd. (Cedar Rapids, Iowa, USA). Kollidon ^TM SR is a product manufactured by BASF (Germany). Encompress is dicalcium phosphate dihydrate which can be purchased from Mandale (Patterson, NY). Tramadol hydrochloride is available from Chemagis (3 Hashlosha Street, PO Box 9091, 61090, Tel Aviv, Israel). Methods for the synthesis and purification of tramadol are described, for example, in US Pat. Nos. 3,652,589, 5,414,129, 5,672,755, 5,874,620, and 5,877,351. And 6,169,205.

(Production method)
The tablets of the present invention can be manufactured according to the method generally described in the flowchart of FIG. 1 and described in more detail below.

  Weighing: Place the ingredients in a clearly labeled container.

  Premixing of the central tablet: Part of Contramid® and colloidal silicon dioxide is sifted through a # 30 mesh sieve and placed in a suitable container.

  Mixing the center tablet: Take a portion of Contramid (registered trademark) and put it in the mixer. Sieve the tramadol hydrochloride through a # 30 mesh sieve and add to the mixer. Rinse the container with a portion of Contramid® and add to the mixer. Sift the hydrogenated vegetable oil type I through a # 30 mesh sieve and add to the mixer. Add the center lock premix to the blender. Place the remaining Contramid® into the blender and mix all ingredients. Sieve the magnesium stearate through a # 30 mesh sieve and add the mixture with the other ingredients. Place the mixture in a suitable container and identify as the center tablet mixture.

  Dry coating premix: Mix a portion of xanthan gum and the entire amount of colloidal silicon dioxide and sift through a # 30 mesh screen.

  Dry coating mixing: Take a portion of Kollidon® SR into a blender. Sieve the tramadol hydrochloride through a Kason separator fitted with a # 30 mesh screen into a suitable container and add to the mixer. Rinse the container with the remaining xanthan gum and add to the mixer. Sieve hydrogenated vegetable oil type 1 with a # 30 mesh sieve and add to the mixer. The dry coating premix and the rest of Kollidon® SR are placed in a blender and all ingredients are mixed. Sieve the magnesium stearate through a # 30 mesh sieve and mix with the other ingredients. Place the granules in a suitable container and identify as a dry coating mixture.

  Compression: Compressed coated tablets are manufactured using Manesty Dry-Cota press.

Example 1
As shown in Table 3, formulations A, B and C were prepared according to the method described above.

  The dissolution profiles of formulations A, B and C are shown in FIG.

(Bioavailability single dose)
(Example 2)
The plasma pharmacokinetic profile of tramadol and its primary metabolite O-desmethyltramadol after a single dose of 200 mg (formulation B) was administered twice a day toparzic®, a currently marketed 100 mg formulation. And compared with twice-daily administration of Topargic (registered trademark), which is a 200 mg preparation currently on the market after administration of a double dose of 200 mg (formulation B). The study is an open single dose randomized three-way crossover design with a washout period of at least 7 days between each dose. The results are shown in FIG. 3 (a) and FIG. 3 (b).

(Example 3)
Plasma pharmacokinetic profiles of tramadol and its primary metabolite O-demethyltramadol after single oral administration of 100, 200 and 300 mg of formulations A, B and C, respectively, were calculated. The study is an open single dose randomized three-way crossover design with a washout period of at least 7 days between each dose. The results are shown in FIGS. 4 (a) and 4 (b).

The median time to maximum plasma concentration of Tramadol (T _max ) is 2 to 8 hours, and the maximum plasma concentration of Tramadol (C _max ) is the mean plasma concentration (C _24h ) obtained 24 hours after a single oral dose of the composition Of less than 3 times. In a narrow sense, the maximum plasma concentration of tramadol (C _max ) obtained for each example is less than twice the plasma concentration (C _24h ) obtained 24 hours after a single dose of the composition of the invention.

Example 4
(steady state)
The steady state plasma pharmacokinetic profile of tramadol and its primary metabolite O-desmethyltramadol after daily administration of 200 mg of formulation B was calculated. Profiles were obtained in a crossover randomized trial corresponding to the open label 2 trial. The results obtained are shown in Table 5.

The present invention is an oral tramadol pharmaceutical composition suitable for continuous administration once a day, wherein the tramadol maximum plasma concentration is 2 to 3 times the minimum tramadol plasma concentration (C _min ) for a given 24 hours in vivo. Compositions comprising an amount of tramadol effective at steady state where (C _max ) is obtained are provided. More preferably, an average C _max of 350 ng / mL or less is obtained. Furthermore, a tramadol plasma concentration that is on average less than 90% of C _max can be achieved for at least 18 hours out of 24 hours.

  The term “λz” is an apparent final disappearance rate constant calculated from the slope of the regression in the log-linear phase.

The term “AUC _0-Tmax ” is the average of the area under the plasma concentration-time curve from time 0 to T _max and is used as an indicator of drug absorption or metabolite formation rate. Calculated as the arithmetic mean of the area under the plasma concentration-time curve from time 0 to _Tmax calculated for each participant in the bioavailability study.

The term “AUC _0-∞ ” is the average of the area under the plasma concentration-time curve extrapolated to infinity. For each participant in the bioavailability study, it is calculated as the arithmetic mean of the area under the plasma concentration-time curve extrapolated from time 0 to infinity.

The term “C ′ _max ” is the highest observed plasma concentration, calculated as the average of each highest plasma concentration.

  The term “half-life” is the apparent final elimination half-life.

The term “HVD” is a half-time, that is, a time for the tramadol concentration to be ½ or more of C ′ _max . This parameter is an indicator of the shape of the plasma concentration time curve, that is, the greater the HVD, the better the release control.

  The term “MRT” is the mean residence time, which is an approximation of the mean time that a tramadol molecule will stay in the body after oral administration.

The term “t _max ” is the time at which C _max is achieved.

The term “T _max ” is the time at which the highest blood concentration was confirmed for each participant in the bioavailability study.

  The term “Rstart” is the time at which the plasma concentration begins to drop in a log-linear form, ie, the time at which drug absorption or metabolite formation is complete.

  The tramadol pharmacokinetic parameters of the controlled release formulation are shown in Table 4, and the pharmacokinetic parameters of O-demethyltramadol of the controlled release formulation are shown in Table 5.

  The present invention is not limited to the scope according to the specific embodiments disclosed in these examples, which are intended to illustrate the scope according to the most preferred embodiments of the present invention. Indeed, various modifications and other embodiments of the invention which are functionally equivalent to those shown and described herein will be apparent to those skilled in the art and are set forth in the appended claims. Intended to be a target. Moreover, while various examples of combined elements of the invention have been described, they are not intended to be exhaustive and the features of one embodiment may be combined with another And other such combinations are intended to be within the scope of the invention disclosed herein.

  Numerous references have been cited, the entire disclosures of which are incorporated herein by reference.

Claims (22)

A central tablet comprising tramadol dispersed in a first controlled release base comprising cross-linked high amylose starch; and a second comprising a mixture of polyvinyl acetate and polyvinylpyrrolidone in a ratio (w / w) of about 8: 2. A solid dosage formulation comprising a compression coating formed over the core tablet, comprising tramadol dispersed in a controlled release base, the mixture being about 30% to 65% by weight of the coating, comprising USP I The release rate of tramadol from the second controlled release base was measured as the rate of release of tramadol from the central tablet when the base was measured individually at 50 to 150 rpm at 50 mM phosphate pH 6.8 using a mold device. Said solid dosage formulation at least twice. The formulation of claim 1, wherein tramadol is present in the formulation as an ionic salt. The formulation according to claim 1, wherein the release rate of tramadol from the coating is 3 to 9 times the release rate of tramadol from the central tablet. The formulation of claim 1, wherein the release rate of tramadol from the coating is at least three times the release rate of tramadol from the central tablet. When tested in vitro with 50-150 rpm stirring in 50 mM phosphoric acid pH 6.8 using a USP Type I apparatus, 10% to 30% of tramadol present at 0 hours is released when measured from 0 to 2 hours. The preparation according to claim 1. When an in vitro test is conducted using a USP Type I apparatus in 50 mM phosphoric acid pH 6.8 with stirring at 50 to 150 rpm, 10% to 40% of tramadol is released from the formulation when measured from 0 to 2 hours. 30 to 60% of the tramadol is released from the preparation at a measurement time of 7 hours to 50% to 80% of the tramadol is released from the preparation at a measurement time of 7 to 12 hours, and after the measurement of about 20 hours from the preparation. 2. A formulation according to claim 1 wherein 80% to 100% of tramadol is released. The formulation of claim 1, wherein the ratio (w / w) of the central tablet to the coating is from about 1 to about 0.1. The formulation of claim 1, wherein the ratio (w / w) of tramadol in the central tablet to tramadol in the coating is from about 0.6 to about 2. The formulation of claim 1, wherein the coating is about 5% to about 90% by weight of tramadol. The formulation of claim 1, wherein the ratio (w / w) of the base of the coating to tramadol in the coating is from about 0.7 to about 4. The formulation of claim 1, wherein the ratio (w / w) of the base of the central tablet to tramadol in the central tablet is from about 0.1 to about 10. The formulation of claim 1, wherein the coating further comprises a binder. 13. A formulation according to claim 12, wherein the binder is xanthan gum. 2. The formulation of claim 1, wherein the formulation is a tablet and the crosslinked high amylose starch (a) crosslinks the high amylose starch, and then (b) the crosslinked high amylose starch by hydroxypropylation. Including chemically modified cross-linked high amylose starch prepared by a process comprising chemically modifying and then (c) gelatinizing and (d) drying to obtain a powder of said controlled release excipient When the cross-linked high amylose starch is subjected to solubilization and gel permeation chromatography for about 3 days in 90% DMSO at 80 ° C., the peak height corresponding to amylose in the cross-linked high amylose starch performs (a) Characterized by being at least 90% of the peak corresponding to amylose in said high amylose starch before Formulation. The formulation according to claim 1, wherein the central tablet further comprises a lubricant. The formulation of claim 1, wherein the coating further comprises a lubricant. The formulation according to claim 1, which is a tablet formulated for oral administration. Pressed central tablet comprising tramadol or a salt thereof and cross-linked high amylose starch; controlled release comprising a coating formed by compression over the central tablet and comprising a mixture of polyvinyl acetate, polyvinylpyrrolidone, binder, and tramadol A center tablet / coating ratio (w / w) of about 0.2 to 0.6, a ratio of tramadol in the central tablet to tramadol in the coating of about 0.7 to about 1, poly When the ratio of vinyl acetate / polyvinylpyrrolidone (w / w) is about 8: 2, and measured at 50 to 150 rpm at 50 mM phosphoric acid pH 6.8 with a USPI type apparatus, the tramadol release rate from the coating is Said controlled release tablet which is at least twice the release rate of 19. The controlled release tablet according to claim 18, wherein the polyvinyl acetate has a molecular weight of 100,000 to 1,000,000. 19. The controlled release tablet according to claim 18, wherein the molecular weight of polyvinylpyrrolidone is 10,000 to 100,000. A once-daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition has an average plasma of at least 100 ng / mL within 2 hours of administration when the first dose is administered 19. The controlled release tablet of claim 18, wherein the controlled release tablet provides a concentration and continues to provide an average plasma concentration of at least 100 ng / mL for at least 22 hours after administration. The controlled-release tablet according to claim 21, wherein the mean maximum plasma concentration ( _Cmax ) is less than 2.2 times the mean plasma concentration ( _C24h ) obtained 24 hours after administration.

Images